BenQ Medical Technology Corporation (TPEX:4116)
Taiwan · Delayed Price · Currency is TWD 39.20
-0.10 (-0.25%)
Aug 19, 2026, 1:30 PM CST
BenQ Medical Technology Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,751 | 1,965 | 2,104 | 2,852 | 2,852 | 1,480 | |
Market Cap Growth | -4.03% | -6.57% | -26.25% | 0% | 92.77% | -8.92% |
Enterprise Value | 4,119 | 3,990 | 3,999 | 4,490 | 3,511 | 1,560 |
Last Close Price | 39.30 | 41.81 | 42.98 | 56.28 | 54.33 | 28.02 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 14.97 | 25.14 | 20.07 | 24.89 | 15.82 | 51.30 |
Forward PE | - | 32.83 | 32.83 | 32.83 | 32.83 | 32.83 |
PS Ratio | 0.32 | 0.37 | 0.44 | 0.63 | 0.65 | 1.01 |
PB Ratio | 0.77 | 0.84 | 0.91 | 1.31 | 1.11 | 1.35 |
P/TBV Ratio | 2.56 | 2.81 | 2.89 | 3.73 | 1.70 | 1.56 |
P/FCF Ratio | 5.06 | 7.42 | 40.35 | 9.23 | 7.03 | 16.24 |
P/OCF Ratio | 4.33 | 5.48 | 9.47 | 6.45 | 5.91 | 12.19 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.76 | 0.76 | 0.84 | 0.99 | 0.80 | 1.07 |
EV/EBITDA Ratio | 6.89 | 7.68 | 7.86 | 8.44 | 6.75 | 14.48 |
EV/EBIT Ratio | 12.09 | 11.65 | 12.01 | 12.29 | 10.02 | 33.57 |
EV/FCF Ratio | 11.91 | 15.07 | 76.71 | 14.54 | 8.65 | 17.12 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.89 | 0.85 | 0.83 | 0.72 | 0.44 | 0.45 |
Debt / EBITDA Ratio | 3.37 | 3.28 | 3.27 | 2.66 | 1.95 | 3.43 |
Debt / FCF Ratio | 5.84 | 7.51 | 36.56 | 5.09 | 2.75 | 5.40 |
Net Debt / Equity Ratio | 0.53 | 0.34 | 0.33 | 0.19 | -0.02 | 0.07 |
Net Debt / EBITDA Ratio | 2.34 | 1.54 | 1.49 | 0.79 | -0.10 | 0.67 |
Net Debt / FCF Ratio | 3.46 | 3.02 | 14.58 | 1.35 | -0.12 | 0.80 |
Asset Turnover | 1.01 | 0.98 | 0.96 | 0.97 | 1.32 | 0.78 |
Inventory Turnover | 4.12 | 4.25 | 5.11 | 6.34 | 8.83 | 4.45 |
Quick Ratio | 0.80 | 0.95 | 1.17 | 1.49 | 1.39 | 1.35 |
Current Ratio | 1.52 | 1.62 | 1.75 | 1.99 | 1.88 | 1.88 |
Return on Equity (ROE) | 12.95% | 9.40% | 10.59% | 8.44% | 12.91% | 4.42% |
Return on Assets (ROA) | 3.95% | 3.99% | 4.17% | 4.86% | 6.59% | 1.55% |
Return on Invested Capital (ROIC) | 6.87% | 7.19% | 8.48% | 9.23% | 14.23% | 3.28% |
Return on Capital Employed (ROCE) | 10.70% | 10.80% | 9.50% | 11.00% | 10.80% | 3.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.72% | 3.98% | 4.98% | 4.02% | 6.32% | 1.95% |
FCF Yield | 19.75% | 13.48% | 2.48% | 10.83% | 14.23% | 6.16% |
Dividend Yield | 5.09% | 4.78% | 3.84% | 3.55% | 3.86% | 1.78% |
Payout Ratio | 62.48% | 94.07% | 85.02% | 144.53% | 42.80% | 154.53% |
Buyback Yield / Dilution | -0.17% | 0.10% | -0.02% | 0.07% | -0.42% | 0.30% |
Total Shareholder Return | 4.92% | 4.88% | 3.82% | 3.62% | 3.44% | 2.08% |